Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Respiratory Distress Syndrome 1Pneumonia, Viral 1Pancreatic Neoplasms 1Glioma 1Cytokine Release Syndrome 1

Interventions

Temozolomide 11Radiotherapy 6Lomustine 3Vincristine 2Procarbazine 2Carmustine 2veliparib 1trametinib 1selinexor 1ribociclib 1lonafarnib 1dabrafenib 1carmustine, poliferprosan 20 drug combination 1Watchful Waiting 1Topotecan 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Conformal 1Psychiatric Rehabilitation 1Platelet Count 1Panobinostat 1Neoadjuvant Therapy 1Mental Status and Dementia Tests 1Magnetic Resonance Spectroscopy 1Imatinib Mesylate 1Hydroxychloroquine 1Everolimus 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Glioma × Hydroxychloroquine × Clear all
NCT04201457 2026-02-03

A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration

Pediatric Brain Tumor Consortium

Phase 1/2 Active not recruiting
57 enrolled
CNS

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡